Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Study Information
Alliance Study ID: A031203
NCT Study ID (ClinicalTrials.gov): NCT01835158
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Genitourinary Cancers – Kidney / Bladder / Urothelial / Testicular
Alliance Study Chair: Toni K Choueiri
Status: COMPLETED
Study Description
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information